<DOC>
	<DOCNO>NCT02475356</DOCNO>
	<brief_summary>The primary objective study collect post-marketing information safety . Thus , include information routine clinical practice adverse event ( AEs ) adverse drug reaction ( ADRs ) include expulsion abnormal bleeding occur within first 12 month Mirena insertion . The secondary objective ( ) study is/are collect information Mirena effectiveness , periodic blood loss Quality life ( QOL ) , use analgesic dysmenorrhea pain far record routine clinical practice .</brief_summary>
	<brief_title>Prospective , Non-interventional , Multi-center Safety Study Mirena Heavy Menstrual Bleeding Dysmenorrhea</brief_title>
	<detailed_description>This local , non-interventional , multicenter , single-cohort study use primary data include patient treat Mirena Heavy menstrual bleeding ( HMB ) and/or dysmenorrhea ( contraception include ) . A total 600 patient ( valid safety analysis ) plan enrol two year . No formal sample size estimation conduct , determine base feasibility . Target population patient HMB and/or dysmenorrhea diagnosis . The treatment perform base product label Japan . The standard observation period last 12 month start Mirena treatment .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Female patient diagnose HMB or/and dysmenorrhea . Patients newly start treatment Mirena make per investigator 's routine treatment practice Written inform consent Patient whose purpose contraception</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mirena</keyword>
	<keyword>Heavy Menstrual Bleeding</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>